| Literature DB >> 30703066 |
Chao Xu1, Xiang-Fei Li1, Hong-Yan Tian2, Hua-Juan Shi1, Ding-Dong Zhang1, Kenneth Prudence Abasubong1, Wen-Bin Liu1.
Abstract
After a 12-week feeding trial, the glucose tolerance test was performed in Megalobrama amblycephala to evaluate the effects of metformin on the metabolic responses of glycolipids. Plasma insulin peaked at 2 h, then decreased to the basal value at 8-12 h post-injection. Plasma triglyceride levels and liver glycogen contents of the control group was decreased significantly during the first 2 and 1 h, respectively. Then, they returned to basal values at 12 h. During the whole sampling period, the high-carbohydrate groups had significantly higher levels of plasma metabolites and liver glycogen than those of the control group, and metformin supplementation enhanced these changes (except insulin levels). Glucose administration lowered the transcriptions of ampk α1, ampk α2, pepck, g6pase, fbpase, cpt IA and aco, the phosphorylation of Ampk α and the activities of the gluconeogenic enzymes during the first 2-4 h, while the opposite was true of glut 2, gs, gk, pk, accα and fas. High-carbohydrate diets significantly increased the transcriptions of ampk α1, ampk α2, glut 2, gs, gk, pk, accα and fas, the phosphorylation of Ampk α and the activities of the glycolytic enzymes during the whole sampling period, while the opposite was true for the remaining indicators. Furthermore, metformin significantly upregulated the aforementioned indicators (except accα and fas) and the transcriptions of cpt IA and aco. Overall, metformin benefits the glucose homeostasis of Megalobrama amblycephala fed high-carbohydrate diets through the activation of Ampk and the stimulation of glycolysis, glycogenesis and fatty acid oxidation, while depressing gluconeogenesis and lipogenesis.Entities:
Keywords: Megalobrama amblycephala ; carbohydrate; glycolipid metabolism; intraperitoneal glucose load; metformin
Year: 2019 PMID: 30703066 PMCID: PMC6391905 DOI: 10.1530/EC-18-0517
Source DB: PubMed Journal: Endocr Connect ISSN: 2049-3614 Impact factor: 3.335
Formulation and proximate composition of the experimental diets.
| C | CM | HC | HCM | |
|---|---|---|---|---|
| Formulation (%) | ||||
| Fish meal | 8.00 | 8.00 | 8.00 | 8.00 |
| Soybean meal | 26.00 | 26.00 | 26.00 | 26.00 |
| Rapeseed meal | 17.00 | 17.00 | 17.00 | 17.00 |
| Cottonseed meal | 17.00 | 17.00 | 17.00 | 17.00 |
| Fish oil | 2.00 | 2.00 | 2.00 | 2.00 |
| Soybean oil | 2.00 | 2.00 | 2.00 | 2.00 |
| Corn starch | 12.00 | 12.00 | 25.00 | 25.00 |
| Metformin | 0 | 0.25 | 0 | 0.25 |
| Microcrystalline cellulose | 13.00 | 13.00 | 0.00 | 0.00 |
| Calcium biphosphate | 1.80 | 1.80 | 1.80 | 1.80 |
| Premixa | 1.20 | 1.20 | 1.20 | 1.20 |
| Proximate composition (% dry matter basis) | ||||
| Moisture | 6.96 | 6.90 | 6.85 | 6.92 |
| Crude lipid | 5.93 | 5.98 | 5.71 | 5.78 |
| Ash | 8.46 | 8.51 | 8.28 | 8.12 |
| Crude protein | 29.82 | 29.91 | 30.12 | 30.31 |
| Crude fiber | 16.97 | 16.82 | 6.18 | 6.29 |
| Nitrogen-free extractb | 31.86 | 31.88 | 42.86 | 42.58 |
| Energy (MJ/kg) | 19.09 | 19.12 | 19.14 | 19.18 |
aPremix supplied the following minerals and/or vitamins (per kg): CuSO4·5H2O, 2.0 g; FeSO4·7H2O, 25 g; ZnSO4·7H2O, 22 g; MnSO4·4H2O, 7 g; Na2SeO3, 0.04|g; KI, 0.026 g; CoCl2·6H2O, 0.1 g; vitamin A, 900,000 IU; vitamin D, 200,000 IU; vitamin E, 4500 mg; vitamin K3, 220 mg; vitamin B1, 320 mg; vitamin B2, 1090 mg; vitamin B5, 2000 mg; vitamin B6, 500 mg; vitamin B12, 1.6 mg; vitamin C, 5000 mg; pantothenate, 1000 mg; folic acid, 165 mg; choline, 60,000 mg. bCalculated by difference (100 − moisture − crude protein − crude lipid − ash − crude fiber).
C, diet with 30% carbohydrate; CM, diet with 30% carbohydrate and 0.25% metformin; HC, diet with 43% carbohydrate; HCM, diet with 43% carbohydrate and 0.25% metformin.
Primers used in the experiment.
| Target gene | Forward (5′-3) | Reverse (5′-3) | Accession numbers or references |
|---|---|---|---|
|
| AGTTGGACGAGAAGGAG | AGGGCATACAAAATCAC | ARF07712.1 |
|
| ACAGCCCTAAGGCACGATG | TGGGTCGGGTAGTGTTGAG | KX061841 |
|
| ACGCACCCGATGTGAAAGT | TTGGACAGCAGCATTGATT | KC513421.1 |
|
| CCTCCAGTAACAACTCACAACA | CAGATAGATTGGTGGTTACGC | 39 |
|
| TGGCCCGTGTGGAGAGTAAAA | ATGTGTTCTGCCAGCCAG | 39 |
|
| TACCCAGATGTCACAGAAT | CACTCATACAACAGCCTCA | KJ743995.1 |
|
| TGAGACCCGGTTTTATGGAG | CATGCAGACCACCAGCTCTA | 39 |
|
| AAAATGCTGCCCACTTAT | AATGCCCTTATCCAAATC | KJ141202.1 |
|
| GCCGAGAAAGTCTTCATCGCACAG | CGTCCAGAACCGCATTAGCCAC | 39 |
|
| AGCGAGTACGGTGATGGT | GGATGATGCCTGAGATGG | KF918747.1 |
|
| TCTGCCCTCTATCTGTCT | ATGCCAATCTCATTTCCT | 39 |
|
| TACTTCCAAAGCGGTGAG | AGAGGTATTGTCCGAGCC | 39 |
|
| GCTCAACCCTGGCATACT | CTGGCTCAGCTTTACACG | 39 |
|
| CTTCTCAGGCTGACTGTGC | CCGCTAGCATTACCCTCC | X77689.1 |
acc α, acetyl-CoA carboxylase α; aco, acyl-CoA oxidase; ampk α1, AMP-activated protein kinase α1; ampk α2, AMP-activated protein kinase α2; cpt IA, carnitine palmitoyl transferase IA; ef 1α, elongation factor 1, α; fas, fatty acid synthetase; fbpase, fructose-1,6-biphosphatase; g6pase, glucose-6-phosphatase; gk, glucokinase; glut 2, glucose transporter 2; gs, glycogen synthase; pepck, phosphoenolpyruvate carboxykinase; pk, pyruvate kinase.
Figure 1Plasma insulin (A) and triglyceride (B) levels and liver glycogen (C) contents of Megalobrama amblycephala subjected to a glucose load after the adaption to different experimental diets. Each data represents the mean ± s.e.m. of four replicates. Significant differences (P < 0.05) among sampling times within each treatment are indicated by the lowercase letters. *Indicates a significant difference (P < 0.05) among these four treatments at each sampling point. ns P > 0.05, *P < 0.05,**P < 0.01, ***P < 0.001.
Figure 2Hepatic transcriptions of ampk α1 (A) and ampk α2 (B) and protein expressions of Ampk α at 2 and 12 h (C) of Megalobrama amblycephala subjected to a glucose load after the adaption to different experimental diets. Each data represents the mean ± s.e.m. of four replicates. Significant differences (P < 0.05) among sampling times within each treatment are indicated by the lowercase letters. *Indicates a significant difference (P < 0.05) among these four treatments at each sampling point. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3Relative transcriptions of glucose metabolism-related genes (glut 2 (A), gs (B), gk (C), pk (D), pepck (E), g6pase (F) and fbpase (G)) in the liver of Megalobrama amblycephala subjected to a glucose load after the adaption to different experimental diets. Each data represents the mean ± s.e.m. of four replicates. Significant differences (P < 0.05) among sampling times within each treatment are indicated by the lowercase letters. *Indicates a significant difference (P < 0.05) among these four treatments at each sampling point. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4The enzymatic activities of glycolysis (GK (A) and PK (B)) and gluconeogenesis (PEPCK (C), G6Pase (D) and FBPase (E)) in the liver of Megalobrama amblycephala subjected to a glucose load after the adaption to different experimental diets. Each data represents the mean ± s.e.m. of four replicates. Significant differences (P < 0.05) among sampling times within each treatment are indicated by the lowercase letters. *Indicates a significant difference (P < 0.05) among these four treatments at each sampling point. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5Relative transcriptions of lipid metabolism-related genes (cpt IA (A), aco (B), accα (C) and fas (D)) in the liver of Megalobrama amblycephala subjected to a glucose load after the adaption to different experimental diets. Each data represents the mean ± s.e.m. of four replicates. Significant differences (P < 0.05) among sampling times within each treatment are indicated by the lowercase letters. *Indicates a significant difference (P < 0.05) among these four treatments at each sampling point. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.